No Data
No Data
Zai Lab Doses First Subject in Phase II Plaque Psoriasis Treatment Trial
Express News | Zaiding Pharmaceutical: ZL-1102 has not been approved in China to treat chronic plaque psoriasis
Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
This is the first compound in Zai's portfolio of internally developed drugs to advance into Phase 2, demonstrating Zai's global capabilities Based on a proof-of-concept study, ZL-1102 is the first topical biologic to
Zai Lab, Innoviva Subsidiary Receive China Approval for Hospital Infection Treatment
Zai Lab (ZLAB) and Innoviva's (INVA) Specialty Therapeutics subsidiary said Monday China's National Medical Products Administration has approved Zai's new drug application for Xacduro, the two firms'
Zai Lab, Innoviva: China Oks XACDURO For Hospital-Acquired, Ventilator-Associated Pneumonia In 18+
Zaiding Pharmaceutical (09688.HK): China Drug Administration approved Dingyule (sulbactam sodium-dulobactan sodium) for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Ba
Zaiding Pharmaceutical (09688.HK) announced that China's State Drug Administration has approved a new drug marketing application for Dingyule (sulbactan sodium-dulobactan sodium) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by sensitive isolates of Baumann-Calcium Acetate Acinetobacter complex in patients aged 18 and above.